CompletedPhase 1NCT03039114
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Fitzroy Dawkins, MDIncyte Corporation
- Intervention
- Parsaclisib(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Study locations (21)
- Banner Health, Gilbert, Arizona, United States
- University of California, San Diego, La Jolla, California, United States
- University of Kansas Cancer Center, Fairway, Kansas, United States
- Center for Cancer and Blood Disorders (CCBD) - Bethesda, Bethesda, Maryland, United States
- Clinical Research Alliance, Lake Success, New York, United States
- Froedtert & Medical College of Wisconsin & Affiliated Hospitals, Milwaukee, Wisconsin, United States
- FN Ostrava / Ostrava, Ostrava, Czechia
- Aarhus University Hospital, Aarhus, Denmark
- Rigshospitalet, Copenhagen, Denmark
- The Finsen Centre, National Hospital, Copenhagen, Denmark
- Semmelweis Egyetem, Budapest, Hungary
- Centro di Riferimento Oncologico, Aviano, Italy
- Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy
- Policlinico S. Orsola-Ematologia LA Seragnoli, Bologna, Italy
- A.O. Spedali Civili, Brescia, Italy
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03039114 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca